Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.

Lorena V BaroniLakshmikirupa SundaresanAyala HeledHallie ColtinKristian W PajtlerTong LinThomas E MerchantRoger E McLendonClaudia FariaMolly BuntineChristine L WhiteStefan M PfisterMark R GilbertTerri S ArmstrongEric BouffetSachin KumarMichael D TaylorKenneth D AldapeDavid W EllisonNicholas G GottardoMarcel KoolAndrey KorshunovJordan R HansfordVijay Ramsawami

Published in: Neuro-oncology (2021)

We have identified an ultra high-risk PF-EPN-A ependymoma subgroup, which can be reliably ascertained using cytogenetic markers in routine clinical use. A change in treatment paradigm is urgently needed for this particular subset of PF-EPN-A where novel therapies should be prioritized for upfront therapy.

Keyphrases

high resolution
clinical practice
gene expression
dna methylation
combination therapy
open label
phase iii
bone marrow
mesenchymal stem cells